Laboratory Medicine is the name of a medical specialty where specialists are involved in medical diagnosis using laboratory assays to characterize molecular and cellular parameters in blood, biological fluids and tissues;
âPUBLIC HEALTH & ITS SUBTLE GROWTHâ đŻPublic health often advances quietly â not through headlines, but through small tools that change outcomes at scale. đA Multiplex is one of those tools: a rapid diagnostic test panel designed to screen for multiple infectious diseases in a single setting. âĄWhile simple in appearance, devices like this sit at the intersection of Epidemiology, Maternal health, and child survival. đ€From an epidemiological standpoint, integrated rapid testing panels are powerful because they support early detection, surveillance, and transmission interruption. đWhen multiple infections can be screened simultaneously, health systems gain faster situational awareness. đ§This is especially critical in low-resource or high-burden settings, where laboratory infrastructure may be limited but disease prevalence may be high. đIn maternal and child health, the stakes are even higher, as vertical transmission â from mother to child during pregnancy, delivery, or breastfeeding â remains a major driver of preventable illness and mortality worldwide. đ€ŒConditions such as blood-borne and sexually transmitted infections can: â Increase risk of miscarriage or stillbirth â Cause congenital infections and birth defects â Lead to preterm birth and low birth weight â Contribute to neonatal and infant mortality â Affect long-term child development outcomes đžEarly screening during antenatal care changes this trajectory. When infections are detected early, interventions can include: â Timely treatment for the mother â Preventive therapies during pregnancy â Safe delivery planning â Postnatal prophylaxis for newborns â Targeted breastfeeding guidance where applicable đČFrom a systems perspective, multi-disease rapid tests also support equity in care delivery. They reduce the number of clinic visits required, lower logistical barriers, and improve coverage in rural and underserved populations. This aligns directly with global goals to strengthen primary healthcare and achieve universal health coverage. đAggregated screening data informs: â Regional disease prevalence trends â Program effectiveness evaluation â Resource allocation decisions â Outbreak early-warning systems đ§âđ§Ultimately, maternal and child health outcomes are one of the clearest indicators of population health. âłïžAs public health professionals, clinicians, policymakers, and community leaders, our challenge is to ensure these tools are accessible, trusted, and integrated into routine care pathways. đBecause sometime, improving global health doesnât start with a breakthrough drug or a new hospital â it starts with making sure a mother has access to a simple test at the right moment. #PublicHealth #Epidemiology #MaternalHealth #ChildHealth #GlobalHealth #PreventiveCare #HealthEquity #PrimaryHealthcare #InfectiousDiseases #AntenatalCare
Une satisfaction đ€ pour le collectif CMSI France qui milite et oeuvre depuis plus de 5 ans sur ce sujet. L'attente fut longue mais çà valait le coup de se battre.
Addis Ababa, Ethiopia From 1 â 9 December 2025, the African Society for Laboratory Medicine (ASLM), with funding from the Fleming Fund through the EQuAFRICA Project piloted the training and certification program for External Quality Assurance Providers (TrEQAP). This is the first of its kind on the African continent. The training program seeks to train [âŠ] The post Training and Certification Program for External Quality Assessment (EQA) Providers â TrEQAP appeared first on ASLM.
How long does Alzheimer's take to progress from its first biological sign to severe dementia? đ§
Understanding this decades long biological timeline is crucial for managing the disease and evaluating new treatments.
A new analysis (https://lnkd.in/gY7igTAC) used longitudinal data from 1,448 subjects in the Alzheimerâs Disease Neuroimaging Initiative (ADNI) and 2,088 subjects in the BioFINDER study. The researchers created a continuous disease timeline by using a modelling technique that aligns patient observations based on amyloid-PET scans and cognitive scales, specifically the MMSE and ADAS-cog.
The timeline is centered at t = 0, which represents the predicted time a subject reaches AÎČ-PET positivity.
The predicted disease time showed a significantly stronger pattern of correlation with unseen validation biomarkers (AÎČ, tau, and neurodegeneration markers) compared to other staging methods, like existing biomarker clocks (all pairwise p values were less than 0.05).
The model revealed a precise sequence of biomarker abnormality, aligning with the disease progression. The total progression from AÎČ-PET positivity to end stage AD dementia (MMSE = 0) was estimated to span 20 to 25 years.
The initial biological sign detectable by biofluid occurred first: CSF AÎČ42/40 became abnormal approximately 1 year prior to AÎČ-PET positivity. The earliest markers of soluble phosphorylated tau followed closely, with CSF p-tau231 and plasma p/np-tau217 becoming abnormal 1 to 3 years after AÎČ-PET positivity.
This change in soluble p-tau happened many years before insoluble tau was detected by imaging, suggesting these soluble markers could reflect early changes caused by AÎČÂ accumulation, not established neurofibrillary tangles.
Insoluble tau pathology, measured by Tau-PET, became clearly abnormal much later, with Braak I regions crossing the abnormality threshold 7 to 9 years after AÎČ-PET positivity. The presymptomatic phase ended and cognitive measures (ADAS-cog/MMSE) become abnormal during the Mild Cognitive Impairment (MCI) stage, 11 to 15 years after AÎČ-PET positivity.
Neurodegeneration, such as loss of hippocampal volume, became clearly abnormal during the dementia stages, 15 to 16 years after AÎČ-PET positivity.
A key limitation of this work is the assumption that AD evolves around a single continuous trajectory; in reality, patient age and co-pathologies can influence the rate of decline and manifestation of symptoms. Also, data reliance on subjects who remain in the study may lead the model to estimate a longer disease duration in the later stages than is seen in typical patient populations.
These models provide continuous time disease staging that could improve prognosis and help in the evaluation of disease modifying treatments, by accurately highlighting the relative timing of pathological events across the AD continuum.
In this video, we explain Laboratory Collection Vials / Blood Collection Tubes, including their color codes, additives, and uses in routine laboratory tests. This video is specially designed for MLT students, lab technicians, and medical students.
đŹ Topics Covered:
What are collection vials?
Color-coded blood collection tubes
Additives present in each vial
Tests performed using each tube
Common mistakes during blood collection
đ This video will help you improve your practical knowledge for exams and clinical laboratory work.
đ Subscribe to MLT Learning Studio for more lab techniques, pathology, microbiology, and hematology videos. MLT Learning Studio Collection vials of laboratory Blood collection tubes Vacutainer tubes Blood vials color code Laboratory practical MLT MLT lab techniques Blood sample collection Hematology tubes Biochemistry blood tubes Pathology lab vials MLT students Pakistan Medical laboratory technology Lab technician training Urdu medical lecturesBlood Collection Tubes Color Code (One by One) 2ïžâŁ EDTA, Citrate, Heparin â Difference 3ïžâŁ Common Errors in Blood Sample Collection 4ïžâŁ Order of Draw in Blood Collection 5ïžâŁ Serum vs Plasma (Practical Explanation)
The Europe clinical laboratory services market to grow from US$ 68.8 Bn in 2025 to US$ 83.2 Bn by 2032, registering a CAGR of 2.4% during 2025â2032...
𧏠Comprehensive Overview of Viral Hepatitis (AâE) A structured understanding of hepatitis is essential for accurate diagnosis, laboratory interpretation, and optimal patient management. Each type exhibits distinct modes of transmission, serological markers, and clinical outcomes. This infographic effectively highlights:
âą Transmission patterns â fecal-oral vs. blood-borne
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Your new post is loading...
